References

- McLaughlin J.R., Lee K.R., "Total Hip Arthroplasty with an Uncemented Femoral Component" JBJS [Br.], 1997, 79B:900–907.
- Hozack W.J., et al., "Primary Cementless Hip Arthroplasty with a Titanium Plasma Sprayed Prosthesis" CORR Number 33-3, December 1996, 217–225.
- Hozack W., "Ten Year Experience with a Wedge-Fit Stem" Presented at Crucial Decisions in TJA and Sports Medicine, Bermuda, 1998.
- 4. McLaughlin J.R., "Plasma Sprayed Porous-Coated Total Hip Arthroplasty: A 13 Year Survivorship Analysis in Patients Age 50 and Under" Presented at the 63rd AAOS, San Francisco, 1997.
- Rothman R.H. and Hozack W.J., "Hydroxyapatite-Coated Femoral Stems" JBJS, 78–A, No. 3, March 1996, 319–324.
- 6. Sharkey P.F., et al., "Initial Stability of a Collarless Wedge-Shaped Prosthesis in the Femoral Canal" Seminars in Arthroplasty, Vol. 1, No. 1, July 1990, 87–90.
- Peyton R., et al., "Uncemented Primary Total Hip Arthroplasty in Octogenarians" Presented at Crucial Decisions in TJA and Sports Medicine, Bermuda, 1999.
- 8. Head W.C., et al., "Comparison of Polyethylene Wear in Machined Versus Molded Polyethylene Liners in RingLoc Acetabular Cups" Presented at Crucial Decisions in TJA and Sports Medicine, Bermuda, 1999.
- Clare I.C., Gustafson A., and Good V., Howard and Irene Peterson Tirbology Laboratory, Department of Orthopedics, Loma Linda University Medical Center. Abstract presented at 7th Annual Conference on Techniques and Science for Successful Joint Arthroplasty, Burlington, Vermont, October 5–6, 1995.
- Schroeder D.H. and Pozorski K.M., "Hip Simulator Wear Testing of Isostatically Molded UHMWPE, Effect of EtO and Gamma Irradiation" 42nd Annual Meeting, Orthopaedic Research Society, February 19–22, 1996, Atlanta, Georgia.
- 11. Rao R.R. et al., "Immediate Weight Bearing After Uncemented Total Hip Arthroplasty" Clinical Orthopaedics, April 1998, 156–162.
- 12. Blunn G.W. et al., "Wear in Retrieved Condylar Knee Arthro-plasties" Journal of Arthroplasty, Vol. 12, No. 3, 1997, 281–290.
- Data derived from Rosner B.I., Postak P.D., Greenwald A.S., "Cup/Liner Conformity of Modular Acetabular Design" Scientific Exhibit presented at the AAOS, 62nd Annual Meeting, Orlando, FL 1995.
- 14. Fehring T.K., et al., "Motion at the Modular Acetabular Shell-Liner Interface: A Comparative Study" Scientific Exhibit presented at the AAOS 63rd Annual Meeting.
- 15. Two-Piece Acetabular Cups, Scientific Exhibit presented at the AAOS, 59th Annual Meeting, San Francisco, CA, 1992. Data derived from Postak P.D., Tradonsky S., Froimson A.I., Greenwald A.S.; "Performance Characteristics of Two-Piece Acetabular Cups Series II" Scientific Exhibit presented at the 63rd Annual Meeting, Atlanta, GA, 1996. This data is the property of the Orthopaedic Research Laboratories of the Mt. Sinai Medical Center, Cleveland, OH. The reproduction and distribution of this data are restricted.
- Markel D.C., et al., "Initial Scratch Fit Stability of Acetabular Cups: Comparison of Three Porous Coated Systems" Presented at the 10th Annual Symposium of the International Society of Technology in Arthroplasty, San Diego, 1997.

TaperLoc[®], RingLoc[®], ArCom[®], Bi-Metric[®], Integral[®], Max-Rom[™] and Mallory-Head[®] are trademarks of Biomet, Inc. Integrity[®] is a registered trademark of Kirschner Medical Corporation, a Biomet, Inc. company. All other trademarks are not associated with Biomet, Inc.









TaperLoc[®] Design Rationale & Surgical Technique

Contents

Design Rationale

-	
Total Hip System	
Offset Variations	
Rotational Fixation.	
Change in Stiffness	
Implant Stability and Fixation	
Plasma Spray Porous Coating	
Consistent Results	
RingLoc Acetabular Series	

Surgical Technique

TaperLoc [®] Surgical Technique	
--	--

Modular Head Options	
TaperLoc Parts Listing	
References	



Disclaimer

Biomet Merck Ltd, as the manufacturer of this device, does not practice medicine and does not recommend this or any other surgical technique for use on a specific patient. The surgeon who performs any procedure is responsible for determining and utilising the appropriate techniques for such procedure for each individual patient. Biomet Merck Ltd is not responsible for selection of the appropriate surgical technique to be utilised for and individual patient.

CE

•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•			•	•	0	.3	
•		•	•	•	•	•	•	•	•	•										•	•	0	.3	
•																						0	.5	
•			•	•	•	•	•	•	•	•				•			•	•	•	•		0	.5	
•																						0	.5	
•			•	•			•	•	•	•										•		0	.7	
•			•	•	•	•	•	•	•	•							•	•	•	•		0	.7	
•																					•	0	.9	
•			•	•			•	•	•	•							•			•	().	10	
•																					.(Э.	12	
•			•			•	•	•	•	•										•	().	13	
•					•	•	•	•	•	•											(Э.	14	

Long-term survivorship with less thigh pain, stress shielding and osteolysis.

99.6%

Survivorship in a series of 4,750 cases over a twelve year period.⁷

98%

Survivorship at 13 years with 100 consecutive implants and 100% follow-up. Average patient age: 37 yrs.⁴

0%

Distal Osteolysis at 8 years.²

TaperLoc[®] Total Hip System

The TaperLoc[®] femoral components evolved from the European philosophy of proportionately designed flat tapered stems, which have been used widely and effectively throughout Europe during the past two decades. From an engineering perspective, there are many theoretical advantages of a flat wedge-shaped collarless design, such as excellent rotational stability and load transfer to the femur. A multitude of clinical studies has concluded that these theoretical advantages do result in less pain and better durability. 1,2,4,6



Offset Variations

likelihood of dislocation. this enhanced stability.

Performance Proven

Introduced in 1983, the TaperLoc® hip had the first primary femoral component offered in the United States with a lateral offset option. Availability of a lateral offset design allows the surgeon to enhance stability without lengthening the leg (Figure 1). The capability of increasing the offset by 6mm helps reduce the

With most systems, lengthening the leg is the only means available to achieve





Fig. 2 A flat wedged design used in the typical ovoid femoral canal provides better rotational stability than those femoral designs based on a round intramedullary rod (Fig. 2). It is generally accepted that rotational stability is the critical parameter for satisfactory fixation and effective pain relief. In a series of tests, Sharkey et al. found the TaperLoc[®] stem to have excellent stability with both axial and rotational loading.⁶



Simply the best



TaperLoc[®] Total Hip System

Rotational Fixation

Change in Stiffness

The tapered titanium geometry, inherent in the TaperLoc[®] stem design, allows for a gradual transition in stiffness from the upper femur, which contains the implant, to the mid femur, which is more flexible (Fig. 3a). With the use of a cobalt chrome intramedullary rod, there will be a more sudden change in stiffness from the extremely rigid upper portion of the femur containing the rod to the more distal portion (Fig. 3b). In fact, the tapered design concept has resulted in a consistently low incidence of thigh pain. 1,2,4

Implant Stability and Fixation

The use of a collarless design in the TaperLoc[®] hip tends to allow for self-seating of the implant and achievement of optimal rotational stability, immediately after implantation. The TaperLoc® collarless stem design leads to dependable fixation and an extremely low rate of revision. $\!\!\!\!^3$

Plasma Spray Porous Coating

Fig. 4

AUTHOR	REFERENCE	HIP IMPLANT SYSTEM	YEARS FOLLOWED	OSTEOLYSIS				
Evans and DeLee Mauerhan, et al. McLaughlin Multi-Center Study	Submitted for Publication J. Arthroplasty, 1997 JBJS Biomet Clin. Report 1994	Bi-Metric [®] (Biomet) Integral [®] (Biomet) TaperLoc [®] (Biomet) TaperLoc [®] Mallory-Head [®] Bi-Metric, [®] Integral [®] (Biomet)	5 – 13 years 5 – 8 years 8 – 12.5 years 5 years	0.0% 0.0% 6.0% 0.4%				
Head, et al. Rothman	Orthopedics 1999 Orthopedics 1994	Mallory-Head [®] (Biomet) TaperLoc [®] (Biomet)	11 years avg. follow-up 7 years	0.0% 3.0%				
Capello, McClain Heekin, et al. Woolson, Maloney Kim, et al. Kim, et al. Smith, Harris Engh	Trans. Int'l Symp 1992 JBJS 1993 J. Arthroplasty, 1992 Orthop. Trans, 1992–93 Orthop. Trans, 1992–93 CORR, 1995 Presentation, 1992	Omnifit [®] (Osteonics) PCA [®] (Howmedica) Harris/Galante [™] (Zimmer) PCA [®] (Howmedica) AML [®] (DePuy) Harris/Galante [™] (Zimmer) AML [®] (DePuy)	2 - 6 years 5 - 7 years 3.5 years avg. follow-up 2 - 7 years 2 - 7 years 4.5 years avg. follow-up 7.5 years avg. follow-up	44.7% 18.0% 22.0% 37.0% 55.8% 31.0% 28.0%				

(ArCom Polyethyl acetabular 40% Reduction	ene In Vivo Wear n in Wear	H
ar (mm³/yr	100		80.81	05 (s)
metric Wea	50	48.71		Rate (10° C
an Volu	0			0 di
Medi	Ū	Compression Molded 1900	Conventional Polyethylene GUR Resin	







Hip Simulator Wear Testing EtO vs. Gamma

Head, et al. Rothman Capello, McCl Heekin, et al. Woolson, Mal Kim, et al. Kim, et al. Smith, Harris Engh Fig. 5





Consistent Results

Through long-term research, laboratory testing, and retrieval analysis, it has been shown that UHMWPE free of defects produces a lower wear rate than material containing defects.¹² Compression molded 1900 resin produces a UHMWPE material with very few, if any, imperfections. The superior results of this material is demonstrated by Head et al. showing a 40% reduction in wear in vivo over conventional polyethylene manufactured from GUR resin.⁸ Compression molded 1900 Resin is the "gold standard" of polyethylene performance.

When Biomet originally considered ways to apply a porous coating on loadbearing implants, sintering of titanium alloy beads was considered but never implemented. Cobalt chrome alloy was also considered, but the greater biocompatibility and superior mechanical and material properties of titanium alloy made it the material of choice. In the early 1980's, a company founder obtained military literature, which described plasma spraying of dense titanium coatings without degradation of the substrate's fatigue strength.

Biomet's proprietary plasma spray application is unique due to the fact that only the titanium alloy powder used to create the coating is heated, not the substrate of the implant-which can lower its mechanical properties. Randomly shaped particles tend to flatten upon impact with the substrate. This generates a random distribution of pore size between 100 and 1,000 microns providing a larger contact area between particles and substrate. Due to the larger distribution of pore size and the enhanced biocompatibility of titanium, bone can grow and mechanically anchor to the implant during all stages of the implant being accepted by the body. This is not the case for sintered beaded or fibre-mesh coatings because they have much larger pores with a very narrow distribution of pore size. The presence of a randomly distributed pore size induces higher initial fixation for Biomet's plasma sprayed implants in comparison to other coated devices.¹⁶

Taking into consideration the above, differences in osteolysis rates may be related to the coating configuration. The TaperLoc[®] stem and all of Biomet's porous coated devices employ this type of plasma spray porous coating. Plasma spray porous coating does not have connecting pores which allow the transport of fluid and debris (Figure 4). This plasma spray has demonstrated excellent aliniaal regulte since 1092 (Figure 5)

The Standard by Which All Others are Judged

RingLoc[®] Acetabular Series

Biomet's RingLoc[®] acetabular components redefine the standard of acetabular technology. The components provide an unparalleled liner locking mechanism, maximum polyethylene thickness and congruity while offering the widest selection of outer shell configurations on the market. The TaperLoc® System is compatible with all RingLoc[®] acetabular components.







Max-Rom[®]

The Max-Rom[®] liners are designed for patients with stable joints at trial reduction who require minimal additional stability. The Max-Rom® provides 125 degrees range of motion, the largest of any liner.

Hi-Wall

The Hi-Wall liner offers an extended polyethylene articulating surface through an arc of 160 degrees about the liner opening to enhance hip stability.

10-Degree

The 10-degree liner shifts the center of rotation anatomically 3.2mm to 5.8mm as the liners get larger. This liner restores the center of rotation of acetabular components which are vertically placed.

TaperLoc[®] Total Hip System

Liner Push-Out/Lever-Out¹⁵

= Initial Lever-Out



Trial Reduction

With the final broach in place, a trial reduction can be accomplished utilizing modular neck provisionals to ensure correct leg length and joint stability. If additional offset is required, "lateralized" head/necks may be utilized to achieve additional horizontal offset.

Step 4.0

Cementless Stems

For cementless stems, the stem corresponding to the size of the final broach can now be implanted into the canal. If desired, an additional trial reduction can be implemented utilising provisional heads to ensure correct leg length and joint stability.

Cemented Stems

Prior to cement and stem insertion, the femoral canal must be throughly debrided of all loose particles. This is best achieved with the use of jet pulse lavage. After debridement, the canal must be throughly dried prior to

The cement is inserted in accordance with the manufacturer's recomendations. For cemented stems, the size implanted also corresponds to the final broach used. (i.e. 12.5mm broach =

During insertion, it is recommended that the stems be inserted into the cement in a continous motion, only stopping when the stem has reached it's final position. Pressure is then maintained upon the stem via the stem insertion instrument until the cement is fully hardened. If desired, another trial reduction can be implemented utilising provisional heads to ensure proper leg length and joint stability.

Step 5.0

Step 5.1

Cemented Modular Femoral Components- Biomet Type 1 Taper

	Tita	anium	Co	ocr
Size (mm)	Standard	Lateralised	Standard	Lateralised
7.5	164414	164421	650-0325	650-0331
10.0	164415	164422	650-0326	650-0332
12.5	164416	164423	650-0327	650-0333
15.0	164417	164424	650-0328	650-0334
17.5	164418	164425	650-0329	650-0335
20.0	164419	164426	650-0330	650-0336

Cementless Modular Femoral Components- Biomet Type 1 Taper

	Tita	inium
Size (mm)	Standard	Lateralised
7.5	164400	103807
9.0	103203	11-103203
10.0	164401	103808
11.0	103205	11-103205
12.5	164402	103809
13.5	103207	11-103207
15.0	164403	103810
17.5	164404	103811
20.0	164405	103812

Primary Instrumentation

Catalogue Number	Description
31-410061	Universal Femoral instrument tray complete with instruments
31-100298	Stem and Modular Head removal tray complete with instruments
31-100683	Modular Head instrument tray complete with instruments - Type 1 Taper
31-100682	Modular Head instrument tray complete with instruments - 12/14 Taper
t.b.a	Impaction Allograft tray No. 1 complete with instruments
t.b.a	Impaction Allograft tray No. 2 complete with instruments

X-Ray Templates

		Magnincation	
Description	110%	115%	120%
Primary Type 1 Taper Templates	31-100710	31-100711	31-100712
Primary 12/14 Taper Templates	31-100376	31-100377	31-100378

Cemented Modular Femoral Components- 12/14 Taper

	Tita	anium	Co	ocr
Size (mm)	Standard	Lateralised	Standard	Lateralised
7.5	650-0313	n/a	650-0337	650-0343
10.0	650-0314	n/a	650-0338	650-0344
12.5	650-0315	n/a	650-0339	650-0345
15.0	650-0316	n/a	650-0340	650-0346
17.5	650-0317	n/a	650-0341	650-0347
20.0	650-0318	n/a	650-0342	650-0348

Cementless Modular Femoral Components- 12/14 Taper

	Titanium				
Size (mm)	Standard	Lateralised			
7.5	650-0319	650-0349			
9.0	650-0260	650-0263			
10.0	650-0320	650-0350			
11.0	650-0261	650-0264			
12.5	650-0321	650-0351			
13.5	650-0262	650-0265			
15.0	650-0322	650-0352			
17.5	650-0323	650-0353			
20.0	650-0324	650-0354			

Modular Head Options



>98% Survivorship Rate at 10 Years⁴

- TaperLoc[®] Hips First 100
- Revisions 0%
- Thigh Pain 3%
- Osteolysis 3%
- 94% of patients demonstrated bone ingrowth
- Average patient age: 82.3 years⁷

- 98% Survivorship at 8 to 13 years with 100 consecutive implants with 100% follow-up⁴
- 99.6% survival rate at up to 12 years in a series of 4,750 cases³

Average patient age: 37 years

- · At an average twoyear follow-up in a matched pair analysis, no clinical data or radiographic advantage was found with the use of hydroxyapatite⁵
- Simultaneous bilateral immediate weight bearing THA with no revisions or femoral loosening¹¹

Magnification

	Cocr	
ard		Later
337		650-
		< = a